PROCEPT BioRobotics Corporation (PRCT)
NEUTRALFundamental
39
मूल्य
$21.43
मार्केट कैप
$1.20B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
बैलेंस शीट और तरलता
राजस्व
$337M
पिछले 12 महीने (30/6/2026 तक)
शुद्ध आय
$-110M
पिछले 12 महीने (30/6/2026 तक)
Free Cash Flow
$-58M
कुल इक्विटी
$366M
कुल देनदारियाँ
$142M
Current Ratio
6.55
Interest Coverage
32.88
Debt/EBITDA
-
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$21.64
वर्तमान मूल्य
$21.43
Margin of Safety
+1.0%
Fair Value सीमा
$20.55 - $22.72
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
-
ROE
-26.1%
P/B Ratio
3.58
P/FCF
-
Gross Margin
64.2%
ROIC
-21.7%
लाभप्रदता Radar
Value Creation (Economic Moat)
ROIC
-21.7%
WACC
9.3%
ROIC − WACC
-31.0 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental विश्लेषण मानदंड
पास (8)
- EPS shows upward trend
- Gross Margin 64.2%
- Debt/Equity ratio
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Revenue Growth 5Y 109.0%
- Analyst Consensus 57% Buy
फेल (12)
- Price CAGR -2.82%
- ROIC -21.7%
- P/B Ratio 3.58
- Operating Margin -33.9%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -30.6%
- Earnings Surprise avg -12.6%
- Share Dilution 6.4%
- Net Margin Trend -32.5% vs -30.6%
- Piotroski F-Score 3/9
अनुपलब्ध (7)
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
गंभीर वित्तीय चिंताएं
Earnings गुणवत्ता
निम्न गुणवत्ता: accounting की जांच करें
शेयर Dilution
नए शेयर जारी कर रही है, स्वामित्व को कम कर रही है
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Mr. Larry L. Wood | President, CEO & Director | 59 |
| Mr. Kevin Waters | Executive VP & CFO | 48 |
| Ms. Alaleh Nouri | EVP, Chief Legal Officer & Corporate Secretary | 46 |
| Mr. Christofer Christoforou | Executive Vice President of Operations | 55 |
| Mr. Barry Templin | Executive VP & CTO | - |
| Mr. Matthew James Bacso C.F.A. | Vice President of Investor Relations | - |
| Ms. Pooja Sharma Rao | Executive VP and Chief Strategy & Marketing Officer | - |
| Ms. Stacey L. Porter | Executive VP & Chief People Officer | 50 |
| Mr. Bijesh Chandran | Executive Vice President of Regulatory Affairs & Quality Assurance | - |
| Mr. Stephen J. McGill | Senior VP & GM of International | 63 |
Audit जोखिम
6
बोर्ड जोखिम
5
मुआवजा जोखिम
10
शेयरधारक अधिकार जोखिम
8
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
Latest News
Recent headlines for PRCT, sourced from Markets Gazette.